The doses of anti-IL-5/Rα biologics used in our study were those used in severe eosinophilic asthma (16, 23), and only one patient received mepolizumab 300 mg, the approved and recommended regimen to treat relapsing or active, non-severe EGPA (4), or the hypereosinophilic syndrome (29). This evidence concerns the gene IL5 and hypereosinophilic syndrome.